Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $15.00 price objective on the stock.

A number of other brokerages have also weighed in on COYA. BTIG Research increased their target price on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Lake Street Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Chardan Capital reissued a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a report on Thursday, January 8th. Finally, Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Price Performance

Shares of COYA opened at $4.85 on Wednesday. Coya Therapeutics has a 1 year low of $3.94 and a 1 year high of $8.29. The stock’s fifty day moving average price is $5.05 and its two-hundred day moving average price is $5.77. The firm has a market cap of $101.46 million, a PE ratio of -4.37 and a beta of 0.27.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. bought a new stake in shares of Coya Therapeutics during the 3rd quarter valued at about $28,000. CIBC Private Wealth Group LLC bought a new stake in Coya Therapeutics during the fourth quarter valued at approximately $47,000. Occudo Quantitative Strategies LP purchased a new position in Coya Therapeutics in the 4th quarter worth approximately $66,000. Lantern Wealth Advisors LLC bought a new position in shares of Coya Therapeutics in the 3rd quarter worth $66,000. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Coya Therapeutics in the 4th quarter worth $81,000. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.